Pharmaceutical Research and Manufacturers of America

Pharmaceutical Research and Manufacturers of America (PhRMA), often referred to as Big Pharma, represents the country's leading biopharmaceutical researchers and biotechnology companies. PhRMA's mission is to conduct effective advocacy for public policies that encourage the discovery of new medicines by pharmaceutical and biotech companies to improve patient health.

History

PhRMA was founded in 1958 as the Pharmaceutical Manufacturers Association. It adopted its current name in 1994 to reflect the growing importance of biotechnology in the development of pharmaceuticals. Since its inception, PhRMA has been a major player in shaping health care policy in the United States and around the world.

Mission and Activities

The primary mission of PhRMA is to advocate for public policies that support the development of innovative medical treatments and cures. This includes lobbying for intellectual property protections, favorable regulations, and tax policies that benefit the pharmaceutical and biotech industries. PhRMA also engages in research and public relations campaigns to promote the value of pharmaceutical innovation.

Membership

PhRMA's membership consists of more than 35 leading pharmaceutical and biotechnology companies. Members must adhere to PhRMA's Code of Conduct, which sets standards for ethical behavior and transparency in their interactions with healthcare professionals and the public.

Controversies

PhRMA has been involved in several controversies, particularly regarding its lobbying efforts to influence healthcare policy and its opposition to drug pricing reforms. Critics argue that PhRMA's activities contribute to high drug prices and limit access to affordable medications.

Impact on Healthcare Policy

PhRMA plays a significant role in shaping healthcare policy in the United States. Its lobbying efforts have influenced legislation related to drug approval processes, patent laws, and Medicare and Medicaid drug coverage. PhRMA's advocacy has contributed to policies that support the pharmaceutical industry's growth and innovation but has also sparked debate about the balance between industry interests and public health needs.

See Also

• Biotechnology
• Drug discovery
• Intellectual property rights in pharmaceuticals
• Healthcare in the United States

‎